Relationship of White Matter Lesions with Intracerebral Hemorrhage Expansion and Functional Outcome: MISTIE II and CLEAR III.

Cerebral hemorrhage Cerebral small vessel diseases Leukoaraiosis Leukoencephalopathies Prognosis Stroke

Journal

Neurocritical care
ISSN: 1556-0961
Titre abrégé: Neurocrit Care
Pays: United States
ID NLM: 101156086

Informations de publication

Date de publication:
10 2020
Historique:
pubmed: 7 2 2020
medline: 30 9 2021
entrez: 7 2 2020
Statut: ppublish

Résumé

Intracerebral hemorrhage (ICH) patients commonly have concomitant white matter lesions (WML) which may be associated with poor outcome. We studied if WML affects hematoma expansion (HE) and post-stroke functional outcome in a post hoc analysis of patients from randomized controlled trials. In ICH patients from the clinical trials MISTIE II and CLEAR III, WML grade on diagnostic computed tomography (dCT) scan (dCT, < 24 h after ictus) was assessed using the van Swieten scale (vSS, range 0-4). The primary outcome for HE was > 33% or > 6 mL ICH volume increase from dCT to the last pre-randomization CT (< 72 h of dCT). Secondary HE outcomes were: absolute ICH expansion, > 10.4 mL total clot volume increase, and a subgroup analysis including patients with dCT < 6 h after ictus using the primary HE definition of > 33% or > 6 mL ICH volume increase. Poor functional outcome was assessed at 180 days and defined as modified Rankin Scale (mRS) ≥ 4, with ordinal mRS as a secondary endpoint. Of 635 patients, 55% had WML grade 1-4 at dCT (median 2.2 h from ictus) and 13% had subsequent HE. WML at dCT did not increase the odds for primary or secondary HE endpoints (P ≥ 0.05) after adjustment for ICH volume, intraventricular hemorrhage volume, warfarin/INR > 1.5, ictus to dCT time in hours, age, diabetes mellitus, and thalamic ICH location. WML increased the odds for having poor functional outcome (mRS ≥ 4) in univariate analyses (vSS 4; OR 4.16; 95% CI 2.54-6.83; P < 0.001) which persisted in multivariable analyses after adjustment for HE and other outcome risk factors. Concomitant WML does not increase the odds for HE in patients with ICH but increases the odds for poor functional outcome. http://www.clinicaltrials.gov trial-identifiers: NCT00224770 and NCT00784134.

Sections du résumé

BACKGROUND/OBJECTIVE
Intracerebral hemorrhage (ICH) patients commonly have concomitant white matter lesions (WML) which may be associated with poor outcome. We studied if WML affects hematoma expansion (HE) and post-stroke functional outcome in a post hoc analysis of patients from randomized controlled trials.
METHODS
In ICH patients from the clinical trials MISTIE II and CLEAR III, WML grade on diagnostic computed tomography (dCT) scan (dCT, < 24 h after ictus) was assessed using the van Swieten scale (vSS, range 0-4). The primary outcome for HE was > 33% or > 6 mL ICH volume increase from dCT to the last pre-randomization CT (< 72 h of dCT). Secondary HE outcomes were: absolute ICH expansion, > 10.4 mL total clot volume increase, and a subgroup analysis including patients with dCT < 6 h after ictus using the primary HE definition of > 33% or > 6 mL ICH volume increase. Poor functional outcome was assessed at 180 days and defined as modified Rankin Scale (mRS) ≥ 4, with ordinal mRS as a secondary endpoint.
RESULTS
Of 635 patients, 55% had WML grade 1-4 at dCT (median 2.2 h from ictus) and 13% had subsequent HE. WML at dCT did not increase the odds for primary or secondary HE endpoints (P ≥ 0.05) after adjustment for ICH volume, intraventricular hemorrhage volume, warfarin/INR > 1.5, ictus to dCT time in hours, age, diabetes mellitus, and thalamic ICH location. WML increased the odds for having poor functional outcome (mRS ≥ 4) in univariate analyses (vSS 4; OR 4.16; 95% CI 2.54-6.83; P < 0.001) which persisted in multivariable analyses after adjustment for HE and other outcome risk factors.
CONCLUSIONS
Concomitant WML does not increase the odds for HE in patients with ICH but increases the odds for poor functional outcome.
CLINICAL TRIAL REGISTRATION
http://www.clinicaltrials.gov trial-identifiers: NCT00224770 and NCT00784134.

Identifiants

pubmed: 32026447
doi: 10.1007/s12028-020-00916-4
pii: 10.1007/s12028-020-00916-4
pmc: PMC7416541
mid: NIHMS1557399
doi:

Substances chimiques

Warfarin 5Q7ZVV76EI

Banques de données

ClinicalTrials.gov
['NCT00224770', 'NCT00784134']

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

516-524

Subventions

Organisme : NINDS NIH HHS
ID : U01 NS062851
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS080824
Pays : United States
Organisme : NCATS NIH HHS
ID : U24 TR001609
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS046309
Pays : United States

Références

Hemphill JC 3rd, Bonovich DC, Besmertis L, Manley GT, Johnston SC. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke. 2001;32:891–7.
doi: 10.1161/01.STR.32.4.891
Hansen BM, Nilsson OG, Anderson H, Norrving B, Säveland H, Lindgren A. Long term (13 years) prognosis after primary intracerebral haemorrhage: a prospective population based study of long term mortality, prognostic factors and causes of death. J Neurol Neurosurg Psychiatry. 2013;84:1150–5.
doi: 10.1136/jnnp-2013-305200
Davis SM, Broderick J, Hennerici M, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006;66:1175–81.
doi: 10.1212/01.wnl.0000208408.98482.99
Steiner T, Diringer MN, Schneider D, et al. Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage: risk factors, clinical impact, and effect of hemostatic therapy with recombinant activated factor VII. Neurosurgery. 2006;59:767–73.
doi: 10.1227/01.NEU.0000232837.34992.32
Brouwers HB, Chang Y, Falcone GJ, et al. Predicting hematoma expansion after primary intracerebral hemorrhage. JAMA Neurol. 2014;71:158–64.
doi: 10.1001/jamaneurol.2013.5433
Huynh TJ, Aviv RI, Dowlatshahi D, et al. Validation of the 9-point and 24-point hematoma expansion prediction scores and derivation of the PREDICT A/B scores. Stroke. 2015;46:3105–10.
doi: 10.1161/STROKEAHA.115.009893
Wang X, Arima H, Al-Shahi Salman R, et al. Clinical prediction algorithm (BRAIN) to determine risk of hematoma growth in acute intracerebral hemorrhage. Stroke. 2015;46:376–81.
doi: 10.1161/STROKEAHA.114.006910
Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9:689–701.
doi: 10.1016/S1474-4422(10)70104-6
Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12:822–38.
doi: 10.1016/S1474-4422(13)70124-8
Gouw AA, Seewann A, van der Flier WM, et al. Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry. 2011;82:126–35.
doi: 10.1136/jnnp.2009.204685
Awad IA, Johnson PC, Spetzler RF, Hodak JA. Incidential subcortical lesions identified on magentic resonance imaging in the elderly. II. Postmortem pathological correlations. Stroke. 1986;17:1090–7.
doi: 10.1161/01.STR.17.6.1090
Lou M, Al-Hazzani A, Goddeau RP Jr, et al. Relationship between white-matter hyperintensities and hematoma volume and growth in patients with intracerebral hemorrhage. Stroke. 2010;41:34–40.
doi: 10.1161/STROKEAHA.109.564955
Sykora M, Herweh C, Steiner T. The association between leukoaraiosis and poor outcome in intracerebral hemorrhage is not mediated by hematoma growth. J Stroke Cerebrovasc Dis. 2017;26:1328–33.
doi: 10.1016/j.jstrokecerebrovasdis.2017.02.003
Morotti A, Shoamanesh A, Oliveira-Filho J, et al. White matter hyperintensities and blood pressure lowering in acute intracerebral hemorrhage: a secondary analysis of the ATACH-2 trial. Neurocrit Care. 2019. https://doi.org/10.1007/s12028-019-00761-0 .
doi: 10.1007/s12028-019-00761-0 pubmed: 31218641 pmcid: 7082383
Folsom AR, Yatsuya H, Mosley TH Jr, Psaty BM, Longstreth WT Jr. Risk of intraparenchymal hemorrhage with magnetic resonance imaging-defined leukoaraiosis and brain infarcts. Ann Neurol. 2012;71:552–9.
doi: 10.1002/ana.22690
Kim BJ, Lee SH, Ryu WS, et al. Extents of white matter lesions and increased intraventricular extension of intracerebral hemorrhage. Crit Care Med. 2013;41:1325–31.
doi: 10.1097/CCM.0b013e31827c05e9
Lee SH, Kim BJ, Ryu WS, et al. White matter lesions and poor outcome after intracerebral hemorrhage: a nationwide cohort study. Neurology. 2010;74:1502–10.
doi: 10.1212/WNL.0b013e3181dd425a
Uniken Venema SM, Marini S, Lena UK, et al. Impact of cerebral small vessel disease on functional recovery after intracerebral hemorrhage. Stroke. 2019. https://doi.org/10.1161/STROKEAHA.119.025061 .
doi: 10.1161/STROKEAHA.119.025061 pubmed: 31446887
Caprio FZ, Maas MB, Rosenberg NF, et al. Leukoaraiosis on magnetic resonance imaging correlates with worse outcomes after spontaneous intracerebral hemorrhage. Stroke. 2013;44:642–6.
doi: 10.1161/STROKEAHA.112.676890
Sato S, Delcourt C, Heeley E, et al. Significance of cerebral small-vessel disease in acute intracerebral hemorrhage. Stroke. 2016;47:701–7.
doi: 10.1161/STROKEAHA.115.012147
Won YS, Chung PW, Kim YB, et al. Leukoaraiosis predicts poor outcome after spontaneous supratentorial intracerebral hemorrhage. Eur Neurol. 2010;64:253–7.
doi: 10.1159/000320972
Tveiten A, Ljøstad U, Mygland Å, Naess H. Leukoaraiosis is associated with short- and long-term mortality in patients with intracerebral hemorrhage. J Stroke Cerebrovasc Dis. 2013;22:919–25.
doi: 10.1016/j.jstrokecerebrovasdis.2013.01.017
Grips E, Sedlaczek O, Bäzner H, Fritzinger M, Daffertshofer M, Hennerici M. Supratentorial age-related white matter changes predict outcome in cerebellar stroke. Stroke. 2005;36:1988–93.
doi: 10.1161/01.STR.0000177869.02361.dc
Galluzzi S, Lanni C, Pantoni L, Filippi M, Frisoni GB. White matter lesions in the elderly: pathophysiological hypothesis on the effect on brain plasticity and reserve. J Neurol Sci. 2008;273:3–9.
doi: 10.1016/j.jns.2008.06.023
Hanley DF, Thompson RE, Muschelli J, et al. Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial. Lancet Neurol. 2016;15:1228–37.
doi: 10.1016/S1474-4422(16)30234-4
Vespa P, Hanley D, Betz J, et al. ICES (intraoperative stereotactic computed tomography-guided endoscopic surgery) for brain hemorrhage: a multicenter randomized controlled trial. Stroke. 2016;47:2749–55.
doi: 10.1161/STROKEAHA.116.013837
Hanley DF, Lane K, McBee N, et al. Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial. Lancet. 2017;389:603–11.
doi: 10.1016/S0140-6736(16)32410-2
van Swieten JC, Hijdra A, Koudstaal PJ, van Gijn J. Grading white matter lesions on CT and MRI: a simple scale. J Neurol Neurosurg Psychiatry. 1990;53:1080–3.
doi: 10.1136/jnnp.53.12.1080
Brouwers HB, Greenberg SM. Hematoma expansion following acute intracerebral hemorrhage. Cerebrovasc Dis. 2013;35:195–201.
doi: 10.1159/000346599
Rodriguez-Luna D, Boyko M, Subramaniam S, et al. Magnitude of Hematoma Volume Measurement Error in Intracerebral Hemorrhage. Stroke. 2016;47:1124–6.
doi: 10.1161/STROKEAHA.115.012170
van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604–7.
doi: 10.1161/01.STR.19.5.604
Wilson JT, Pettigrew LE, Teasdale GM. Structured interviews for the glasgow outcome scale and the extended glasgow outcome scale: guidelines for their use. J Neurotrauma. 1998;15:573–85.
doi: 10.1089/neu.1998.15.573
Wartenberg KE, Mayer SA. Ultra-early hemostatic therapy for intracerebral hemorrhage: future directions. Front Neurol Neurosci. 2015;37:107–29.
doi: 10.1159/000437117
Hansen BM, Ullman N, Norrving B, Hanley DF, Lindgren A. Applicability of clinical trials in an unselected cohort of patients with intracerebral hemorrhage. Stroke. 2016;47:2634–7.
doi: 10.1161/STROKEAHA.116.014203
Wahlund LO, Barkhof F, Fazekas F, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32:1318–22.
doi: 10.1161/01.STR.32.6.1318
Venkatasubramanian C, Mlynash M, Finley-Caulfield A, et al. Natural history of perihematomal edema after intracerebral hemorrhage measured by serial magnetic resonance imaging. Stroke. 2011;42:73–80.
doi: 10.1161/STROKEAHA.110.590646

Auteurs

Björn M Hansen (BM)

Department of Clinical Sciences Lund, Neurology, Skåne University Hospital, Lund University, Lund, Sweden.

Natalie Ullman (N)

Division of Neurology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA. nlullman@gmail.com.

John Muschelli (J)

Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Bo Norrving (B)

Department of Clinical Sciences Lund, Neurology, Skåne University Hospital, Lund University, Lund, Sweden.

Rachel Dlugash (R)

Division of Brain Injury Outcomes, Johns Hopkins University, Baltimore, MD, USA.

Radhika Avadhani (R)

Division of Brain Injury Outcomes, Johns Hopkins University, Baltimore, MD, USA.

Issam Awad (I)

Department of Neurosurgery, University of Chicago, Chicago, IL, USA.

Mario Zuccarello (M)

Department of Neurosurgery, University of Cincinnati, Cincinnati, OH, USA.

Wendy C Ziai (WC)

Division of Brain Injury Outcomes, Johns Hopkins University, Baltimore, MD, USA.

Daniel F Hanley (DF)

Division of Brain Injury Outcomes, Johns Hopkins University, Baltimore, MD, USA.

Richard E Thompson (RE)

Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Arne Lindgren (A)

Department of Clinical Sciences Lund, Neurology, Skåne University Hospital, Lund University, Lund, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH